Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), today announced that it has recruited Jakob Dynnes Hansen as its Chief Financial Officer to succeed Henrik Moltke, who will continue as CFO of Scandinavian Micro Biodevices that was recently acquired by Zoetis.
Jakob joins Acesion from Evolva, a Swiss biotech company, where he has been CFO since 2007 and where he played a key role in the company’s public listing in 2009 and subsequent public financings. Prior to that Jakob was CFO of Nuevolution A/S and Zealand Pharma A/S and had senior roles at a Scandinavian investment bank and at Novo Nordisk A/S. Jakob will also continue to perform services for Evolva while the company is transitioning to a new CFO.
CEO of Acesion Pharma, Frans Wuite, comments:
“We are delighted to have Jakob onboard at an important time for our company as we are soon moving into the clinical stage of development. Jakob has a long-standing track record in financial management and corporate development of life science companies and in negotiation and execution of major corporate and financing transactions.”